<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729596</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGC018-01</org_study_id>
    <nct_id>NCT03729596</nct_id>
  </id_info>
  <brief_title>MGC018 With or Without MGA012 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)&#xD;
      pharmacodynamics and preliminary antitumor activity of MGC018 administered alone and in&#xD;
      combination with MGA012 in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1/2 study will characterize safety, dose-limiting toxicities (DLTs), and maximum&#xD;
      tolerated/administered dose (MTD/MAD) and anti-tumor activity for MGC018 as monotherapy&#xD;
      (Module A) in patients with advanced solid tumors. Each module consists of a Dose Escalation&#xD;
      (3+3+3 design) followed by a Cohort Expansion Phase. Patients with solid tumors will be&#xD;
      enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic&#xD;
      castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC),&#xD;
      triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN),&#xD;
      and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for&#xD;
      permanent discontinuation may undergo additional cycles for up to two years. Patients in&#xD;
      Cohort Expansion will be followed for survival every 3 months for 2 years following last&#xD;
      dose.&#xD;
&#xD;
      Module B, MGC018 in combination with MGA012, Dose Escalation and Cohort Expansion will&#xD;
      commence only upon sponsor notification to all study investigators.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation will use a 3+3+3 design to identify an MAD or MTD, followed by a Cohort Expansion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events of MGC018 and MGC018 + MGA012 as assessed by CTCAE v4.03</measure>
    <time_frame>30 days after last dose</time_frame>
    <description>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>up to 42 days from first dose</time_frame>
    <description>Maximum tolerated or maximum administered dose of MGC018 and MGC018 + MGA012</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity of MGC018 and MGC018+MGA012</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy assessed as best overall response rate using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>24 months</time_frame>
    <description>Percent of prostate cancer patients with at least 50% reduction in prostate-specific antigen (PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best PSA response</measure>
    <time_frame>24 months</time_frame>
    <description>The greatest change from baseline in PSA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>For prostate cancer patients, time from first dose to first radiographic progression in soft tissue or bone, or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Outcome</measure>
    <time_frame>24 months</time_frame>
    <description>For prostate cancer patients, change from baseline in pain intensity as measured by the Brief Pain Inventory-Short Form scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>24 months</time_frame>
    <description>Area under the plasma concentration versus time curve of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Plasma Concentration of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>24 months</time_frame>
    <description>Trough plasma concentration of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>24 months</time_frame>
    <description>Total body clearance of the drug from plasma of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>24 months</time_frame>
    <description>Apparent volume of distribution at steady state of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>24 months</time_frame>
    <description>Terminal half life of MGC018 and MGC018+MGA012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>24 months</time_frame>
    <description>Percent of patients with anti-drug antibodies against MGC018 and MGA012</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Advanced Solid Tumor, Adult</condition>
  <condition>Metastatic Castrate Resistant Prostate Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MGC018 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGC018: Anti-B7-H3 antibody drug conjugate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MGC018 plus MGA012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGC018: Anti-B7-H3 antibody drug conjugate; MGA012: Anti-PD-1 antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGC018</intervention_name>
    <description>Anti-B7-H3 antibody drug conjugate</description>
    <arm_group_label>MGC018 Monotherapy</arm_group_label>
    <arm_group_label>MGC018 plus MGA012</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGA012</intervention_name>
    <description>Anti-PD-1 antibody</description>
    <arm_group_label>MGC018 plus MGA012</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Tissue specimen available for retrospective analysis of B7-H3 and PD-L1 expression.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of ≤2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks for dose escalation phase and ≥ 24 weeks for cohort&#xD;
             expansion phase&#xD;
&#xD;
          -  Measurable disease. Prostate cancer patients with bone only disease are eligible.&#xD;
&#xD;
          -  Acceptable laboratory parameters and adequate organ reserve.&#xD;
&#xD;
          -  Dose Escalation Phase: Patients with histologically proven, unresectable, locally&#xD;
             advanced or metastatic solid tumors for whom no therapy with demonstrated clinical&#xD;
             benefit is available.&#xD;
&#xD;
        Module A Cohort Expansion:&#xD;
&#xD;
          -  mCRPC that has progressed with one prior line of chemotherapy for metastatic disease&#xD;
             and no more than two prior lines of anti-hormonal therapy.&#xD;
&#xD;
          -  NSCLC: metastatic disease after standard cytotoxic, targeted, and biologic or&#xD;
             checkpoint inhibitor therapy. No more than 2 prior lines of chemotherapy.&#xD;
&#xD;
          -  TNBC: Locally advance or metastatic disease that has progressed following at least one&#xD;
             systemic therapy.&#xD;
&#xD;
          -  SCCHN that has progressed during or following at least one systemic therapy for&#xD;
             metastatic or recurrent unresectable disease. No more than 2 prior lines of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Melanoma that has progressed during or following at least one systemic treatment for&#xD;
             unresectable locally advanced or metastatic disease. Patients who are intolerant of or&#xD;
             refused standard therapy are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of prior central nervous system (CNS) metastasis must have been&#xD;
             treated, be asymptomatic, and not have concurrent treatment for CNS disease,&#xD;
             progression of CNS metastases on MRI, CT or PET within 6 months, or history of&#xD;
             leptomeningeal disease or cord compression at the time of enrollment.&#xD;
&#xD;
          -  Prior treatment with B7-H3 targeted agents for cancer.&#xD;
&#xD;
          -  Treatment with systemic cancer therapy, biologic agents, or anti-hormonal therapy&#xD;
             (mCRPC) within 4 weeks, prior small molecule targeted or kinase inhibitors within 14&#xD;
             days or 5 half-lives, prior radioligand within 6 months&#xD;
&#xD;
          -  Clinically significant cardiovascular disease.&#xD;
&#xD;
          -  Clinically significant pulmonary compromise or requirement for supplemental oxygen.&#xD;
&#xD;
          -  History of clinically-significant cardiovascular disease, including but not limited to&#xD;
             pericarditis or pericardial effusion.&#xD;
&#xD;
          -  Active viral (including confirmed or presumed COVID-19), bacterial, or systemic fungal&#xD;
             infection requiring parenteral treatment within 7 days of first study drug&#xD;
             administration.&#xD;
&#xD;
          -  Known history of hepatitis B or C infection or known positive test for hepatitis B&#xD;
             surface antigen or core antigen, or hepatitis C polymerase chain reaction.&#xD;
&#xD;
          -  Known positive testing for human immunodeficiency virus or history of acquired immune&#xD;
             deficiency syndrome.&#xD;
&#xD;
          -  Major trauma or major surgery within 4 weeks of first study drug administration.&#xD;
&#xD;
          -  Clinically significant venous insufficiency.&#xD;
&#xD;
          -  &gt; Grade 1 peripheral neuropathy.&#xD;
&#xD;
          -  Evidence of pleural effusion.&#xD;
&#xD;
          -  Evidence of ascites.&#xD;
&#xD;
          -  Serum testosterone &gt;50 ng/dl or &gt;1.7 nmol/L in mCRPC in Module A Cohort Expansion&#xD;
             Phase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chet Bohac, PharmD MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Lohr, PhD</last_name>
    <phone>(240) 552-8030</phone>
    <email>lohrj@macrogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Department of Medicine - Hematology/Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Hilburn, RN</last_name>
      <phone>310-633-8400</phone>
      <email>khilburn@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>John Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kshitij Neupane</last_name>
      <phone>202-660-5377</phone>
      <email>kneupan2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Channing Paller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sin Chan, MS</last_name>
      <phone>410-614-3630</phone>
      <email>schan33@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene Shenderov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Bartz</last_name>
      <phone>402-354-7939</phone>
      <email>Kathryn.bartz@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Kirsten Leu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maira Galvan</last_name>
      <phone>702-862-8687</phone>
      <email>maira.galvan@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Vicuna</last_name>
      <phone>(702) 968-3880</phone>
      <email>Melissa.Vicuna@USONCOLOGY.COM</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Carolina Biooncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaelyn Rose Linski, MA</last_name>
      <phone>704-947-6599</phone>
      <phone_ext>111</phone_ext>
      <email>jlinski@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>John Powderly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords</last_name>
      <email>Kelly.jeffords@inova.org</email>
    </contact>
    <investigator>
      <last_name>Sekwon Jang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Philips</last_name>
      <phone>703-208-9268</phone>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Health Network (Kinghorn Cancer Centre)</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Douglas</last_name>
      <phone>+61 2 9355 5618</phone>
      <email>Ashley.Douglas@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Anthony Joshua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health - Olivia Newton John Cancer Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naila Pachani</last_name>
      <phone>+61 3 9496 9118</phone>
      <email>naila.pachani@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Andrew Weickhardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Calvary Mater NewCastle</name>
      <address>
        <city>Waratah</city>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerrie Cornall</last_name>
      <phone>+61 2 4014 3280</phone>
      <email>kerrie.cornall@calvarymater.org.au</email>
    </contact>
    <investigator>
      <last_name>Girish Mallesara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Queensland - Princess Alexandra Hospital (PAH)</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4105</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wangyi Jiang</last_name>
      <phone>+61 7 3176 8295</phone>
      <email>Wangyi.Juang@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Wen Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Oddział Kliniczny Onkologii</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Wysocki</last_name>
      <phone>48 12 424 89 12</phone>
      <email>piotr.wysocki@uj.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Wysocki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med-Polonia Sp. z o.o.</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodryg Ramlau</last_name>
      <phone>48505758992</phone>
      <email>rramlau@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rodryg Ramlau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Oddział Badań Wczesnych Faz</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Dylewska-Rzeznik</last_name>
      <phone>48 22 546 26 94</phone>
      <email>Joanna.Dylewska-Rzeznik@pib-nio.pl</email>
    </contact>
    <investigator>
      <last_name>Iwona Lugowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magodent Sp. z o.o. Szpital Elbląska Oddział Onkologii Klinicznej/ Chemioterapii</name>
      <address>
        <city>Warszawa</city>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakub Żołnierek</last_name>
      <phone>48 22 430 88 50</phone>
      <email>qbazolnier@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Jakub Żołnierek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Valverde</last_name>
      <phone>34 93 274 60 00</phone>
      <email>operationalnursing@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Elena Garralda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>20850</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María de Miguel</last_name>
      <phone>34 91 756 78 25</phone>
      <email>maria.demiguel@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Lopez</last_name>
      <phone>91 387 50 90</phone>
      <email>patricia.lopez.munoz@iob-onco.com</email>
    </contact>
    <investigator>
      <last_name>Javier Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibody-drug conjugate (ADC)</keyword>
  <keyword>B7-H3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

